TR201904459T4 - Bir mitotik inhibitör ile kombinasyon terapisi. - Google Patents
Bir mitotik inhibitör ile kombinasyon terapisi.Info
- Publication number
- TR201904459T4 TR201904459T4 TR2019/04459T TR201904459T TR201904459T4 TR 201904459 T4 TR201904459 T4 TR 201904459T4 TR 2019/04459 T TR2019/04459 T TR 2019/04459T TR 201904459 T TR201904459 T TR 201904459T TR 201904459 T4 TR201904459 T4 TR 201904459T4
- Authority
- TR
- Turkey
- Prior art keywords
- inhibitors
- alkylating agents
- combination therapy
- mitotic inhibitor
- anticancer drugs
- Prior art date
Links
- 229940121849 Mitotic inhibitor Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 229940100198 alkylating agent Drugs 0.000 abstract 3
- 239000002168 alkylating agent Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 241000219198 Brassica Species 0.000 abstract 1
- 235000003351 Brassica cretica Nutrition 0.000 abstract 1
- 235000003343 Brassica rupestris Nutrition 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 235000010460 mustard Nutrition 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 108010049948 plitidepsin Proteins 0.000 abstract 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 abstract 1
- 229950008499 plitidepsin Drugs 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382300 | 2010-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201904459T4 true TR201904459T4 (tr) | 2019-05-21 |
Family
ID=44936282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/04459T TR201904459T4 (tr) | 2010-11-12 | 2011-11-11 | Bir mitotik inhibitör ile kombinasyon terapisi. |
| TR2019/03859T TR201903859T4 (tr) | 2010-11-12 | 2011-11-11 | Bir antitümör antibiyotik ile kombinasyon terapisi. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03859T TR201903859T4 (tr) | 2010-11-12 | 2011-11-11 | Bir antitümör antibiyotik ile kombinasyon terapisi. |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20130266666A1 (enExample) |
| EP (6) | EP2786754B1 (enExample) |
| JP (4) | JP6382516B2 (enExample) |
| KR (9) | KR20170057472A (enExample) |
| CN (3) | CN106860870B (enExample) |
| AU (4) | AU2011328004C1 (enExample) |
| BR (4) | BR112013011480B1 (enExample) |
| CA (4) | CA2995033C (enExample) |
| CY (4) | CY1117466T1 (enExample) |
| DK (4) | DK2637663T3 (enExample) |
| ES (4) | ES2719091T3 (enExample) |
| HK (1) | HK1202422A1 (enExample) |
| HR (4) | HRP20160361T1 (enExample) |
| HU (4) | HUE042801T2 (enExample) |
| LT (3) | LT2786753T (enExample) |
| ME (3) | ME02395B (enExample) |
| PL (4) | PL2786756T3 (enExample) |
| PT (3) | PT2786754T (enExample) |
| RS (4) | RS58608B1 (enExample) |
| RU (4) | RU2605335C2 (enExample) |
| SI (4) | SI2786754T1 (enExample) |
| SM (4) | SMT202000211T1 (enExample) |
| TR (2) | TR201904459T4 (enExample) |
| WO (1) | WO2012062920A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| PL2786756T3 (pl) * | 2010-11-12 | 2020-07-13 | Pharma Mar, S.A. | Terapia skojarzona z inhibitorem topoizomerazy |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| KR101588949B1 (ko) * | 2014-03-13 | 2016-01-29 | 아주대학교산학협력단 | 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제 |
| EP3292218A4 (en) * | 2015-01-30 | 2019-01-16 | Glax LLC | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, FORECASTING, DETECTION AND TREATMENT OF CANCER |
| MX2018008321A (es) * | 2016-01-11 | 2018-09-21 | Syndevrx Inc | Tratamiento de tumores ocasionados por disfuncion metabolica. |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| AU2019366819C1 (en) | 2018-10-26 | 2025-12-18 | Syndevrx Inc. | Biomarkers of MetAP2 inhibitors and applications thereof |
| AU2020342483A1 (en) * | 2019-09-03 | 2022-04-14 | Pharma Mar, S.A. | Lurbinectedin in the treatment of malignant mesothelioma |
| KR20210049403A (ko) * | 2019-10-25 | 2021-05-06 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 조성물 |
| WO2021228414A1 (en) * | 2020-05-14 | 2021-11-18 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| MA56827B2 (fr) * | 2019-11-21 | 2023-09-27 | Pharma Mar Sa | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine |
| JOP20220118A1 (ar) * | 2019-11-21 | 2023-01-30 | Pharma Mar Sa | طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين |
| CN111298122B (zh) * | 2019-12-04 | 2021-12-21 | 哈尔滨商业大学 | 用于治疗小细胞肺癌的药物组合物及其应用 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113491771A (zh) * | 2020-03-18 | 2021-10-12 | 苏州大学 | 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用 |
| EP4141110A4 (en) | 2020-04-24 | 2025-04-09 | Sf Biotech Laboratuvar Danismanlik Anonim Sirketi | Method for producing particles of bacteriophages of the genus levivirus |
| US20230255947A1 (en) * | 2020-07-01 | 2023-08-17 | National Cancer Center | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING 3-KETOACYL CoA THIOLASE INHIBITOR AND CARNITINE ACYLCARNITINE CARRIER INHIBITOR |
| CN118576601A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗结肠癌的药物中的用途 |
| CN112870194B (zh) * | 2021-01-06 | 2022-06-21 | 广州医科大学附属肿瘤医院 | 治疗肝癌的组合物及其应用 |
| CN115957188A (zh) * | 2021-06-17 | 2023-04-14 | 中国医学科学院医药生物技术研究所 | 米铂脂质体在抗耐药性肿瘤的应用 |
| CN115246846B (zh) * | 2021-11-19 | 2024-10-01 | 江苏慧聚药业股份有限公司 | 卢比替定新晶型及其制备 |
| WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
| WO2024188978A1 (en) * | 2023-03-10 | 2024-09-19 | Pharma Mar, S.A. | Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer |
| EP4563149A1 (en) * | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
| WO2025228597A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer |
| WO2025228596A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
| JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| DE3774435D1 (de) | 1986-06-09 | 1991-12-12 | Univ Pennsylvania | Ekteinascidine 729, 743, 745, 759a, 759b and 770. |
| US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| PL196809B1 (pl) | 1998-04-06 | 2008-02-29 | Univ Illinois | Półsyntetyczne ekteinascydyny, kompozycje farmaceutyczne oraz zastosowanie półsyntetycznych ekteinascydyn |
| HUP0101960A3 (en) | 1998-05-11 | 2003-03-28 | Pharma Mar Sa | Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them |
| US6124292A (en) | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| JP2003520801A (ja) | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成 |
| DE60111845T2 (de) | 2000-04-12 | 2006-04-27 | Pharma Mar, S.A., Tres Cantos | Ecteinaschidin derivate mit antikrebs wirkung |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| IL155781A0 (en) * | 2000-11-06 | 2003-12-23 | Pharma Mar Sa | Effective antitumor treatments |
| SE0102232L (sv) * | 2001-06-25 | 2003-02-06 | Anoto Ab | Förfarande och anordning i ett digitalt kommunikationssystem |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| GEP20074134B (en) * | 2002-08-19 | 2007-06-25 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases |
| CN100591691C (zh) | 2002-10-18 | 2010-02-24 | 马尔药品公司 | 新型抗肿瘤化合物 |
| FR2856688B1 (fr) | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| US7393277B2 (en) * | 2003-08-25 | 2008-07-01 | Igt | Horseshoe payline system and games using that system |
| US7622458B2 (en) * | 2003-11-13 | 2009-11-24 | Pharma Mar, S.A.U. | Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment |
| AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| EP1771174A1 (en) * | 2004-05-28 | 2007-04-11 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| DE602005001833T2 (de) | 2004-10-29 | 2008-04-17 | Pharma Mar S.A., Sociedad Unipersonal | Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide |
| AU2005316652B2 (en) | 2004-12-15 | 2009-07-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combinations of therapeutic agents for treating cancer |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| KR20140101014A (ko) * | 2006-02-28 | 2014-08-18 | 파르마 마르 에스.에이. | 개선된 항종양 치료 |
| EP2307003A2 (en) * | 2008-05-16 | 2011-04-13 | Pharma Mar S.A. | Combination therapy with pm00104 and another antitumor agent |
| PL2786756T3 (pl) * | 2010-11-12 | 2020-07-13 | Pharma Mar, S.A. | Terapia skojarzona z inhibitorem topoizomerazy |
-
2011
- 2011-11-11 PL PL14175282T patent/PL2786756T3/pl unknown
- 2011-11-11 KR KR1020177013349A patent/KR20170057472A/ko not_active Withdrawn
- 2011-11-11 PL PL11781807T patent/PL2637663T3/pl unknown
- 2011-11-11 DK DK11781807.0T patent/DK2637663T3/en active
- 2011-11-11 KR KR1020217011747A patent/KR102452022B1/ko active Active
- 2011-11-11 BR BR112013011480-0A patent/BR112013011480B1/pt active IP Right Grant
- 2011-11-11 PT PT14175268T patent/PT2786754T/pt unknown
- 2011-11-11 TR TR2019/04459T patent/TR201904459T4/tr unknown
- 2011-11-11 JP JP2013538215A patent/JP6382516B2/ja active Active
- 2011-11-11 US US13/884,874 patent/US20130266666A1/en not_active Abandoned
- 2011-11-11 ES ES14175268T patent/ES2719091T3/es active Active
- 2011-11-11 KR KR1020177022534A patent/KR20170096224A/ko not_active Ceased
- 2011-11-11 CA CA2995033A patent/CA2995033C/en active Active
- 2011-11-11 RS RS20190380A patent/RS58608B1/sr unknown
- 2011-11-11 CA CA2995025A patent/CA2995025C/en active Active
- 2011-11-11 BR BR122017028570-0A patent/BR122017028570B1/pt active IP Right Grant
- 2011-11-11 KR KR1020197033700A patent/KR102301175B1/ko active Active
- 2011-11-11 BR BR122017028568-8A patent/BR122017028568B1/pt active IP Right Grant
- 2011-11-11 ES ES11781807.0T patent/ES2569180T3/es active Active
- 2011-11-11 EP EP14175268.3A patent/EP2786754B1/en active Active
- 2011-11-11 SI SI201131698T patent/SI2786754T1/sl unknown
- 2011-11-11 HU HUE14175268A patent/HUE042801T2/hu unknown
- 2011-11-11 SI SI201131699T patent/SI2786753T1/sl unknown
- 2011-11-11 CA CA2817420A patent/CA2817420C/en active Active
- 2011-11-11 ME MEP-2016-54A patent/ME02395B/me unknown
- 2011-11-11 KR KR1020137015020A patent/KR101716804B1/ko active Active
- 2011-11-11 PL PL14175259T patent/PL2786753T3/pl unknown
- 2011-11-11 AU AU2011328004A patent/AU2011328004C1/en active Active
- 2011-11-11 ES ES14175282T patent/ES2790414T3/es active Active
- 2011-11-11 EP EP14175282.4A patent/EP2786756B1/en active Active
- 2011-11-11 HU HUE14175282A patent/HUE049389T2/hu unknown
- 2011-11-11 SI SI201130769A patent/SI2637663T1/sl unknown
- 2011-11-11 ME MEP-2019-77A patent/ME03501B/me unknown
- 2011-11-11 DK DK14175259.2T patent/DK2786753T3/en active
- 2011-11-11 PT PT14175259T patent/PT2786753T/pt unknown
- 2011-11-11 WO PCT/EP2011/069976 patent/WO2012062920A1/en not_active Ceased
- 2011-11-11 HU HUE14175259A patent/HUE042802T2/hu unknown
- 2011-11-11 RU RU2013126630/15A patent/RU2605335C2/ru active
- 2011-11-11 LT LTEP14175259.2T patent/LT2786753T/lt unknown
- 2011-11-11 KR KR1020177013350A patent/KR20170058454A/ko not_active Withdrawn
- 2011-11-11 RS RS20200506A patent/RS60236B1/sr unknown
- 2011-11-11 SM SM20200211T patent/SMT202000211T1/it unknown
- 2011-11-11 CN CN201710123189.7A patent/CN106860870B/zh active Active
- 2011-11-11 TR TR2019/03859T patent/TR201903859T4/tr unknown
- 2011-11-11 EP EP14175275.8A patent/EP2786755A3/en not_active Withdrawn
- 2011-11-11 KR KR1020177031575A patent/KR102247982B1/ko active Active
- 2011-11-11 LT LTEP14175282.4T patent/LT2786756T/lt unknown
- 2011-11-11 ME MEP-2019-91A patent/ME03408B/me unknown
- 2011-11-11 KR KR1020167019709A patent/KR20160088956A/ko not_active Ceased
- 2011-11-11 ES ES14175259T patent/ES2719052T3/es active Active
- 2011-11-11 EP EP14175259.2A patent/EP2786753B1/en active Active
- 2011-11-11 RU RU2016144668A patent/RU2743643C2/ru active
- 2011-11-11 SM SM20190186T patent/SMT201900186T1/it unknown
- 2011-11-11 EP EP20155618.0A patent/EP3666275A3/en not_active Withdrawn
- 2011-11-11 DK DK14175282.4T patent/DK2786756T3/da active
- 2011-11-11 PT PT141752824T patent/PT2786756T/pt unknown
- 2011-11-11 HU HUE11781807A patent/HUE027516T2/en unknown
- 2011-11-11 RS RS20160181A patent/RS54648B1/sr unknown
- 2011-11-11 EP EP11781807.0A patent/EP2637663B1/en active Active
- 2011-11-11 PL PL14175268T patent/PL2786754T3/pl unknown
- 2011-11-11 KR KR1020177022535A patent/KR20170096065A/ko not_active Ceased
- 2011-11-11 LT LTEP14175268.3T patent/LT2786754T/lt unknown
- 2011-11-11 CA CA2995018A patent/CA2995018C/en active Active
- 2011-11-11 RS RS20190397A patent/RS58609B1/sr unknown
- 2011-11-11 DK DK14175268.3T patent/DK2786754T3/en active
- 2011-11-11 SM SM20190190T patent/SMT201900190T1/it unknown
- 2011-11-11 SI SI201131880T patent/SI2786756T1/sl unknown
- 2011-11-11 HR HRP20160361TT patent/HRP20160361T1/hr unknown
- 2011-11-11 CN CN201180063925.5A patent/CN103282037B/zh active Active
- 2011-11-11 BR BR122017028566-1A patent/BR122017028566B1/pt active IP Right Grant
- 2011-11-11 CN CN201610032547.9A patent/CN105664165A/zh active Pending
-
2014
- 2014-02-24 HK HK15102911.5A patent/HK1202422A1/en unknown
-
2016
- 2016-01-13 AU AU2016200191A patent/AU2016200191B2/en active Active
- 2016-04-19 SM SM201600112T patent/SMT201600112B/it unknown
- 2016-04-22 CY CY20161100333T patent/CY1117466T1/el unknown
- 2016-05-02 JP JP2016092369A patent/JP6723815B2/ja active Active
-
2017
- 2017-09-21 US US15/711,478 patent/US20180008602A1/en not_active Abandoned
- 2017-11-28 US US15/824,551 patent/US11590129B2/en active Active
- 2017-11-28 US US15/824,506 patent/US20180078550A1/en not_active Abandoned
- 2017-12-11 AU AU2017276157A patent/AU2017276157B2/en active Active
- 2017-12-11 AU AU2017276155A patent/AU2017276155B2/en active Active
-
2018
- 2018-01-19 RU RU2018102080A patent/RU2767664C2/ru active
- 2018-01-19 RU RU2018102078A patent/RU2757373C2/ru active
- 2018-03-27 JP JP2018059776A patent/JP6724055B2/ja active Active
- 2018-03-27 JP JP2018059777A patent/JP6724056B2/ja active Active
-
2019
- 2019-03-21 HR HRP20190554TT patent/HRP20190554T1/hr unknown
- 2019-03-22 HR HRP20190565TT patent/HRP20190565T1/hr unknown
- 2019-03-29 CY CY20191100362T patent/CY1121501T1/el unknown
- 2019-03-29 CY CY20191100361T patent/CY1121504T1/el unknown
-
2020
- 2020-04-30 HR HRP20200696TT patent/HRP20200696T1/hr unknown
- 2020-05-08 CY CY20201100423T patent/CY1122904T1/el unknown
-
2023
- 2023-01-11 US US18/095,877 patent/US20230404999A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201904459T4 (tr) | Bir mitotik inhibitör ile kombinasyon terapisi. | |
| CR20130247A (es) | Compuestos tricíclicos de la pi3k y métodos de uso | |
| EP2899199A4 (en) | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate | |
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2015002591A1 (es) | Entidades químicas. | |
| PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| EA201270264A1 (ru) | Лечение метастазов в головной мозг ингибиторами рецепторов эндотелина в комбинации с цитотоксическим химиотерапевтическим средством | |
| GEP20217330B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| MA32547B1 (fr) | Antagonistes specifiques du recepteur fgf-r4 | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| MX2009008470A (es) | Particulas para detectar objetivos intracelulares. | |
| EA201390695A1 (ru) | Способы лечения рака | |
| Burslem et al. | Scaffold hopping enables direct access to more potent PROTACs with in vivo activity | |
| IN2012DN03178A (enExample) | ||
| IL201012A0 (en) | Quinoline derivatives as crth2 receptor ligands | |
| WO2012019132A3 (en) | Anaplastic lymphoma kinase in kidney cancer | |
| AR070456A1 (es) | Combinacion que comprende paclitaxel para el tratamiento de cancer de ovario y su uso | |
| MX2015010407A (es) | Heterociclos triciclicos como agentes anticancer. | |
| TR200802713A2 (tr) | Demir eksikliği tedavisi için demir çinko esaslı bir farmasötik formülasyon | |
| EP3968417A4 (en) | POWER STORAGE DEVICE BINDER COMPOSITION, POWER STORAGE DEVICE ELECTRODE SLURRY, POWER STORAGE DEVICE ELECTRODE AND POWER STORAGE DEVICE | |
| CL2008001322A1 (es) | Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| WO2011138449A3 (en) | Antagonists of sema3e/plexind1 interaction as anti-cancer agents | |
| MX2011008870A (es) | Tope de empaque. |